Physician profile
William B Perry
NPI 1538184635
$4,479.39
in general payments reported to CMS, 2019-2025
36 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $687 · 2021: $714 · 2022: $639 · 2023: $646 · 2024: $679 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $611.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.34 | 2019-2025 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $325.76 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $324.70 | 2019-2024 | |
| Pfizer INC. | $294.98 | 2019-2025 | |
| Lilly USA, LLC | $284.10 | 2019-2025 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $226.51 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $208.05 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $191.22 | 2020-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $176.17 | 2019-2023 | |
| Astellas Pharma US INC | $150.76 | 2022-2025 | Veozah |
| Amgen INC. | $129.57 | 2019-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $115.12 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $97.75 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.68 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $80.93 | 2019-2020 | |
| Novo Nordisk INC | $70.04 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.51 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $62.84 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $60.51 | 2019-2022 | |
| Axsome Therapeutics, INC. | $57.34 | 2024 | Auvelity |
| Exact Sciences Corporation | $53.38 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $39.48 | 2021-2023 | Glassia |
| Antares Pharma, INC. | $37.22 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Genentech USA, INC. | $35.24 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.70 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $26.50 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.45 | 2024 | Voquezna |
| Lundbeck LLC | $21.36 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $18.34 | 2025 | |
| Tolmar, INC. | $17.63 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $16.58 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $15.38 | 2021 | |
| Boston Scientific Corporation | $15.25 | 2022 | |
| Philips North America LLC | $15.13 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.